References
- Merion RM. Current status and future of liver transplantation. Semin Liv Dis. 2010;30(4):411–21.
- Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142(6):1373–83.
- Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al.. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–6.
- Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–87.
- Singhal A, Jain AB, Burke M, Black M. Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection. Exp Clin Transplant. 2010;8(3):214–9.
- Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al.. Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;25:2609–17.
- von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al.. Peginterferon-alpha-2a (40 kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129(2):522–7.
- Guido M, Rugge M, Colombari R, Cecchetto A, Scarpa A, Cadrobbi P, et al.. Prompt hepatitis C virus suppression following hepatitis B superinfection in chronic untreated hepatitis C. J Gastroenterol Hepatol. 1998;30:414.
- Gruener NH, Jung MC, Ulsenheimer A, Gerlach TJ, Diepolder HM, Schirren CA, et al.. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J Hepatol. 2002;37:886–69.
- Biliotti E, Kondili LA, Furlan C, Ferretti G, Zacharia S, de Angelis M, et al.. Acute hepatitis B in patients with or without underlying chronic HCV infection. J Infect. 2008;57(2):152–7.
- Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, et al.. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009;49(4):1090–7.
- Ganem D, Prince AM. Hepatitis B viral infection — natural history and clinical consequences. New Engl J Med. 2004;350:1118–29.
- Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol. 1995;13:29–60.
- Maini MK, Boni C, Ogg GS, King AS, Reignat S, Lee CK, et al.. Direct ex vivo analysis of hepatitis B virus specific CD8+ T cell associated with the control of infection. Gastroenterology. 1999;117:1386–96.
- Billiau A. The mode of action of interferons in viral infections and their possible role in the control of hepatitis B. J Hepatol. 1986;3(Suppl 2):S171–9.
- Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284:825–9.
- Mele A, Spada E, Sagliocca L, Ragni P, Tosti ME, Gallo G, et al.. Risk of parenteraly transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. J Hepatol. 2001;35:284–9.
- Knöll A, Pietrzyk M, Loss M, Goetz WA, Jilg W. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation. 2005;79(11):1631–3.
- Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol. 2012; (Epub ahead of print).
- Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004;19:715–27.
- Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.
- Ying C, Colonno R, de Clercq E, Neyts J. Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of Entecavir. Antiviral Res. 2007;73(3):192–6.